Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Sinopharm Group Co ( (HK:1099) ).
Sinopharm Group has scheduled a board meeting for April 24, 2026, to review and approve the unaudited quarterly results for the three months ended March 31, 2026. The announcement signals the forthcoming release of key financial data that will offer investors and stakeholders an early view of the group’s operating performance and business momentum in the first quarter of 2026.
The notice also reconfirms the current composition of Sinopharm Group’s board, which includes executive, non-executive and independent non-executive directors, underscoring its adherence to corporate governance norms required for Hong Kong-listed companies. Market participants may watch the upcoming results for indications of trends in China’s pharmaceutical distribution sector and the company’s positioning within it.
The most recent analyst rating on (HK:1099) stock is a Hold with a HK$21.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical distributor and healthcare services provider, listed in Hong Kong and incorporated as a joint stock limited company in the People’s Republic of China. The group operates through numerous subsidiaries across the pharmaceutical supply chain, focusing on medicine distribution, healthcare logistics and related services in mainland China and Hong Kong.
Average Trading Volume: 5,656,890
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.78B
For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.